S&P 500   4,027.81
DOW   32,717.60
QQQ   312.72
3 Undervalued Dividend Payers For Volatile Market Conditions
BREAKING: Tiny biotech successfully treats blindness (Ad)
3 More Downgrades To Put On Your Buy List 
Three Pullback Opportunities in Tech Right Now
BREAKING: Tiny biotech successfully treats blindness (Ad)
Three Mid Caps Wall Street Sees Doubling Within 12 Months
The Most Important Warren Buffett Stock for Investors: His Own
Modern Day Options Trading For Beginners! (Ad)pixel
Dave & Buster’s Rebound Could Score for Investors 
Micron Technology Goes on Breakout Watch
S&P 500   4,027.81
DOW   32,717.60
QQQ   312.72
3 Undervalued Dividend Payers For Volatile Market Conditions
BREAKING: Tiny biotech successfully treats blindness (Ad)
3 More Downgrades To Put On Your Buy List 
Three Pullback Opportunities in Tech Right Now
BREAKING: Tiny biotech successfully treats blindness (Ad)
Three Mid Caps Wall Street Sees Doubling Within 12 Months
The Most Important Warren Buffett Stock for Investors: His Own
Modern Day Options Trading For Beginners! (Ad)pixel
Dave & Buster’s Rebound Could Score for Investors 
Micron Technology Goes on Breakout Watch
S&P 500   4,027.81
DOW   32,717.60
QQQ   312.72
3 Undervalued Dividend Payers For Volatile Market Conditions
BREAKING: Tiny biotech successfully treats blindness (Ad)
3 More Downgrades To Put On Your Buy List 
Three Pullback Opportunities in Tech Right Now
BREAKING: Tiny biotech successfully treats blindness (Ad)
Three Mid Caps Wall Street Sees Doubling Within 12 Months
The Most Important Warren Buffett Stock for Investors: His Own
Modern Day Options Trading For Beginners! (Ad)pixel
Dave & Buster’s Rebound Could Score for Investors 
Micron Technology Goes on Breakout Watch
S&P 500   4,027.81
DOW   32,717.60
QQQ   312.72
3 Undervalued Dividend Payers For Volatile Market Conditions
BREAKING: Tiny biotech successfully treats blindness (Ad)
3 More Downgrades To Put On Your Buy List 
Three Pullback Opportunities in Tech Right Now
BREAKING: Tiny biotech successfully treats blindness (Ad)
Three Mid Caps Wall Street Sees Doubling Within 12 Months
The Most Important Warren Buffett Stock for Investors: His Own
Modern Day Options Trading For Beginners! (Ad)pixel
Dave & Buster’s Rebound Could Score for Investors 
Micron Technology Goes on Breakout Watch
NASDAQ:KZR

Kezar Life Sciences - KZR Stock Forecast, Price & News

$3.23
+0.02 (+0.62%)
(As of 03/29/2023 12:00 AM ET)
Add
Compare
Today's Range
$3.18
$3.35
50-Day Range
$3.21
$7.31
52-Week Range
$3.17
$17.87
Volume
1.97 million shs
Average Volume
825,648 shs
Market Capitalization
$228.70 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$18.33

Kezar Life Sciences MarketRank™ Forecast

Analyst Rating
Moderate Buy
2.67 Rating Score
Upside/​Downside
467.6% Upside
$18.33 Price Target
Short Interest
Bearish
6.91% of Shares Sold Short
Dividend Strength
N/A
Sustainability
-0.85
Upright™ Environmental Score
News Sentiment
0.25mentions of Kezar Life Sciences in the last 14 days
Based on 2 Articles This Week
Insider Trading
Selling Shares
$1.71 M Sold Last Quarter
Proj. Earnings Growth
Decreasing
From ($1.18) to ($1.32) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.12 out of 5 stars

Medical Sector

469th out of 999 stocks

Pharmaceutical Preparations Industry

220th out of 489 stocks


KZR stock logo

About Kezar Life Sciences (NASDAQ:KZR) Stock

Kezar Life Sciences, Inc. is a clinical-stage biopharmaceutical company which engages in the development of novel small molecule therapeutics to treat autoimmunity and cancer. Its product pipeline includes KZR-616, KZR-261, and KZR-TBD. The company was founded by John Fowler, Christopher J. Kirk, and Jack Taunton on February 20, 2015 and is headquartered in South San Francisco, CA.

Receive KZR Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Kezar Life Sciences and its competitors with MarketBeat's FREE daily newsletter.

KZR Stock News Headlines

Buy THIS stock before Taiwan is attacked
... If the United States goes to war with another nuclear armed superpower, this could have a devastating impact on your retirement portfolio. Now, even Taiwan's own foreign minister is saying that China is on the cusp of a full scale invasion. But the good news is, if China invades Taiwan, there is a way to protect yourself.
My No. 1 dividend stock for a LIFETIME of income.
Few people realize this… But dividends account for up to 90% of the stock market's returns over the past century!  I think it's a crying shame folks don't know how powerful dividends are.
KZR Kezar Life Sciences, Inc.
Wells Fargo Reaffirms Their Buy Rating on Kezar Life Sciences (KZR)
Kezar Life Sciences
See More Headlines
Receive KZR Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Kezar Life Sciences and its competitors with MarketBeat's FREE daily newsletter.

KZR Company Calendar

Last Earnings
11/09/2021
Today
3/29/2023
Next Earnings (Estimated)
5/11/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:KZR
Fax
N/A
Employees
56
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$18.33
High Stock Price Forecast
$21.00
Low Stock Price Forecast
$14.00
Forecasted Upside/Downside
+467.6%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.67
Research Coverage
3 Analysts

Profitability

Net Income
$-68,240,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
$3.95 per share

Miscellaneous

Free Float
65,281,000
Market Cap
$228.70 million
Optionable
Not Optionable
Beta
0.25

Key Executives

  • John Fowler
    Chief Executive Officer & Director
  • Christopher J. Kirk
    President, Director & Chief Scientific Officer
  • Michael Wolfe
    Director-Finance & Business Operations
  • Marc L. BelskyMarc L. Belsky
    Chief Financial Officer & Secretary
  • Noreen Roth Henig
    Chief Medical Officer













KZR Stock - Frequently Asked Questions

Should I buy or sell Kezar Life Sciences stock right now?

3 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Kezar Life Sciences in the last twelve months. There are currently 1 hold rating and 2 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" KZR shares.
View KZR analyst ratings
or view top-rated stocks.

What is Kezar Life Sciences' stock price forecast for 2023?

3 Wall Street analysts have issued 1 year target prices for Kezar Life Sciences' shares. Their KZR share price forecasts range from $14.00 to $21.00. On average, they expect the company's stock price to reach $18.33 in the next twelve months. This suggests a possible upside of 467.6% from the stock's current price.
View analysts price targets for KZR
or view top-rated stocks among Wall Street analysts.

How have KZR shares performed in 2023?

Kezar Life Sciences' stock was trading at $7.04 at the beginning of 2023. Since then, KZR shares have decreased by 54.1% and is now trading at $3.23.
View the best growth stocks for 2023 here
.

Are investors shorting Kezar Life Sciences?

Kezar Life Sciences saw a increase in short interest in the month of March. As of March 15th, there was short interest totaling 4,890,000 shares, an increase of 13.2% from the February 28th total of 4,320,000 shares. Based on an average daily volume of 714,700 shares, the days-to-cover ratio is currently 6.8 days.
View Kezar Life Sciences' Short Interest
.

When is Kezar Life Sciences' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, May 11th 2023.
View our KZR earnings forecast
.

How were Kezar Life Sciences' earnings last quarter?

Kezar Life Sciences, Inc. (NASDAQ:KZR) posted its quarterly earnings data on Tuesday, November, 9th. The company reported ($0.28) earnings per share for the quarter, missing the consensus estimate of ($0.26) by $0.02.

What ETFs hold Kezar Life Sciences' stock?

ETFs with the largest weight of Kezar Life Sciences (NASDAQ:KZR) stock in their portfolio include Virtus LifeSci Biotech Clinical Trials ETF (BBC), ALPS Medical Breakthroughs ETF (SBIO) and SPDR S&P Biotech ETF (XBI).Direxion Daily S&P Biotech Bull 3x Shares (LABU).

What other stocks do shareholders of Kezar Life Sciences own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Kezar Life Sciences investors own include VBI Vaccines (VBIV), OPKO Health (OPK), Sorrento Therapeutics (SRNE), Pfizer (PFE), VYNE Therapeutics (vyne), Dynavax Technologies (DVAX), Gilead Sciences (GILD), AbbVie (ABBV), Aldeyra Therapeutics (ALDX) and Exelixis (EXEL).

When did Kezar Life Sciences IPO?

(KZR) raised $70 million in an initial public offering (IPO) on Thursday, June 21st 2018. The company issued 4,700,000 shares at $14.00-$16.00 per share. Jefferies, Cowen, Wells Fargo Securities and William Blair served as the underwriters for the IPO.

What is Kezar Life Sciences' stock symbol?

Kezar Life Sciences trades on the NASDAQ under the ticker symbol "KZR."

Who are Kezar Life Sciences' major shareholders?

Kezar Life Sciences' stock is owned by a number of institutional and retail investors. Top institutional shareholders include Avidity Partners Management LP (9.92%), Millennium Management LLC (4.24%), Sphera Funds Management LTD. (1.91%), JPMorgan Chase & Co. (1.57%), Geode Capital Management LLC (1.43%) and Granahan Investment Management LLC (1.01%). Insiders that own company stock include Equal Talent Investments Ltd, Franklin M Berger, Michael Kauffman and Morningside Venture Investment.
View institutional ownership trends
.

How do I buy shares of Kezar Life Sciences?

Shares of KZR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Kezar Life Sciences' stock price today?

One share of KZR stock can currently be purchased for approximately $3.23.

How much money does Kezar Life Sciences make?

Kezar Life Sciences (NASDAQ:KZR) has a market capitalization of $228.70 million. The company earns $-68,240,000.00 in net income (profit) each year or ($1.01) on an earnings per share basis.

How can I contact Kezar Life Sciences?

Kezar Life Sciences' mailing address is 4000 SHORELINE COURT SUITE 300, SOUTH SAN FRANCISCO CA, 94080. The official website for the company is www.kezarlifesciences.com. The company can be reached via phone at (650) 822-5600 or via email at ceconomides@kezarbio.com.

This page (NASDAQ:KZR) was last updated on 3/30/2023 by MarketBeat.com Staff